124 related articles for article (PubMed ID: 29902477)
1. Development of a Vaginal Fast-Dissolving Insert Combining Griffithsin and Carrageenan for Potential Use Against Sexually Transmitted Infections.
Lal M; Lai M; Ugaonkar S; Wesenberg A; Kizima L; Rodriguez A; Levendosky K; Mizenina O; Fernández-Romero J; Zydowsky T
J Pharm Sci; 2018 Oct; 107(10):2601-2610. PubMed ID: 29902477
[TBL] [Abstract][Full Text] [Related]
2. Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo.
Derby N; Lal M; Aravantinou M; Kizima L; Barnable P; Rodriguez A; Lai M; Wesenberg A; Ugaonkar S; Levendosky K; Mizenina O; Kleinbeck K; Lifson JD; Peet MM; Lloyd Z; Benson M; Heneine W; O'Keefe BR; Robbiani M; Martinelli E; Grasperge B; Blanchard J; Gettie A; Teleshova N; Fernández-Romero JA; Zydowsky TM
Nat Commun; 2018 Sep; 9(1):3881. PubMed ID: 30250170
[TBL] [Abstract][Full Text] [Related]
3. Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan.
Elias CJ; Coggins C; Alvarez F; Brache V; Fraser IS; Lacarra M; Lähteenmäki P; Massai R; Mishell DR; Phillips DM; Salvatierra AM
Contraception; 1997 Dec; 56(6):387-9. PubMed ID: 9494773
[TBL] [Abstract][Full Text] [Related]
4. Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel.
Teleshova N; Keller MJ; Fernández Romero JA; Friedland BA; Creasy GW; Plagianos MG; Ray L; Barnable P; Kizima L; Rodriguez A; Cornejal N; Melo C; Cruz Rodriguez G; Mukhopadhyay S; Calenda G; Sinkar SU; Bonnaire T; Wesenberg A; Zhang S; Kleinbeck K; Palmer K; Alami M; O'Keefe BR; Gillevet P; Hur H; Liang Y; Santone G; Fichorova RN; Kalir T; Zydowsky TM
PLoS One; 2022; 17(1):e0261775. PubMed ID: 35051209
[TBL] [Abstract][Full Text] [Related]
5. Carrageenan-Based Acyclovir Mucoadhesive Vaginal Tablets for Prevention of Genital Herpes.
Pacheco-Quito EM; Ruiz-Caro R; Rubio J; Tamayo A; Veiga MD
Mar Drugs; 2020 May; 18(5):. PubMed ID: 32403219
[TBL] [Abstract][Full Text] [Related]
6. pH-responsive delivery of Griffithsin from electrospun fibers.
Tyo KM; Duan J; Kollipara P; Dela Cerna MVC; Lee D; Palmer KE; Steinbach-Rankins JM
Eur J Pharm Biopharm; 2019 May; 138():64-74. PubMed ID: 29698714
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of protein stability in rod-insert vaginal rings.
Pattani A; Lowry D; Curran RM; McGrath S; Kett VL; Andrews GP; Malcolm RK
Int J Pharm; 2012 Jul; 430(1-2):89-97. PubMed ID: 22486955
[TBL] [Abstract][Full Text] [Related]
8. Developing a Flexible Pediatric Dosage Form for Antiretroviral Therapy: A Fast-Dissolving Tablet.
Lal M; Lai M; Estrada M; Zhu C
J Pharm Sci; 2017 Aug; 106(8):2173-2177. PubMed ID: 28499879
[TBL] [Abstract][Full Text] [Related]
9. Acceptability of a carrageenan-based candidate vaginal microbicide and matching placebo: findings from a phase II safety trial among women in Chiang Rai, Thailand.
Jones HE; Chaikummao S; van de Wijgert JH; Friedland BA; Manopaiboon C; Witwatwongwana P; Wankrairot M; Chantharojwong N; Kilmarx PH
J Womens Health (Larchmt); 2009 Jul; 18(7):1003-10. PubMed ID: 19575689
[TBL] [Abstract][Full Text] [Related]
10. Effect of carrageenan on poloxamer-based in situ gel for vaginal use: Improved in vitro and in vivo sustained-release properties.
Liu Y; Zhu YY; Wei G; Lu WY
Eur J Pharm Sci; 2009 Jun; 37(3-4):306-12. PubMed ID: 19491020
[TBL] [Abstract][Full Text] [Related]
11. Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV Infection.
Grooms TN; Vuong HR; Tyo KM; Malik DA; Sims LB; Whittington CP; Palmer KE; Matoba N; Steinbach-Rankins JM
Antimicrob Agents Chemother; 2016 Nov; 60(11):6518-6531. PubMed ID: 27550363
[TBL] [Abstract][Full Text] [Related]
12. The Role of Volume in the Perceptibility of Topical Vaginal Formulations: User Sensory Perceptions and Experiences of Heterosexual Couples During Vaginal Sex.
Guthrie KM; Fava JL; Vargas SE; Rosen RK; Shaw JG; Kojic EM; Ham AS; Rohan LC; Katz D; Panameño A; Colleran C; Friend DF; Buckheit KW; Buckheit RW
AIDS Res Hum Retroviruses; 2020 Dec; 36(12):1059-1070. PubMed ID: 32988214
[TBL] [Abstract][Full Text] [Related]
13. Freeze-dried cylinders carrying chitosan nanoparticles for vaginal peptide delivery.
Marciello M; Rossi S; Caramella C; Remuñán-López C
Carbohydr Polym; 2017 Aug; 170():43-51. PubMed ID: 28522002
[TBL] [Abstract][Full Text] [Related]
14. Freeze-dried mucoadhesive polymeric system containing pegylated lipoplexes: Towards a vaginal sustained released system for siRNA.
Furst T; Dakwar GR; Zagato E; Lechanteur A; Remaut K; Evrard B; Braeckmans K; Piel G
J Control Release; 2016 Aug; 236():68-78. PubMed ID: 27329774
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398.
Grammen C; Van den Mooter G; Appeltans B; Michiels J; Crucitti T; Ariën KK; Augustyns K; Augustijns P; Brouwers J
Int J Pharm; 2014 Nov; 475(1-2):238-44. PubMed ID: 25175729
[TBL] [Abstract][Full Text] [Related]
16. Crystallizing amino acids as bulking agents in freeze-drying.
Horn J; Tolardo E; Fissore D; Friess W
Eur J Pharm Biopharm; 2018 Nov; 132():70-82. PubMed ID: 30201570
[TBL] [Abstract][Full Text] [Related]
17. Preformulation Characterization of Griffithsin, a Biopharmaceutical Candidate for HIV Prevention.
Kramzer LF; Hamorsky KT; Graebing PW; Wang L; Fuqua JL; Matoba N; Lasnik AB; Moncla BJ; Zhang J; Palmer KE; Rohan LC
AAPS PharmSciTech; 2021 Feb; 22(3):83. PubMed ID: 33625602
[TBL] [Abstract][Full Text] [Related]
18. Rapid-Release Griffithsin Fibers for Dual Prevention of HSV-2 and HIV-1 Infections.
Tyo KM; Lasnik AB; Zhang L; Jenson AB; Fuqua JL; Palmer KE; Steinbach-Rankins JM
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32229493
[TBL] [Abstract][Full Text] [Related]
19. Freeze-Drying of L-Arginine/Sucrose-Based Protein Formulations, Part 2: Optimization of Formulation Design and Freeze-Drying Process Conditions for an L-Arginine Chloride-Based Protein Formulation System.
Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
J Pharm Sci; 2015 Dec; 104(12):4241-4256. PubMed ID: 26422647
[TBL] [Abstract][Full Text] [Related]
20. The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention.
Ham AS; Nugent ST; Peters JJ; Katz DF; Shelter CM; Dezzutti CS; Boczar AD; Buckheit KW; Buckheit RW
Antiviral Res; 2015 Aug; 120():153-64. PubMed ID: 26093158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
